Guangwei Li,
Of 981 adults ages 60 or older with prediabetes who were followed for 12 years, 204 (22%) reverted to normoglycemia and 119 (13%) developed diabetes,
In a four-armed intervention study of adults with impaired glucose tolerance or newly diagnosed
PREVIEW is the largest randomized control trial (gold standard of clinical trials) to date on the prevention of type 2 diabetes in adults with prediabetes through diet and exercise. Participants
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Hertzel C Gersteinet al
ABSTRACT
Summary Background
Two glucagon-like peptide-1 (GLP-1) receptor agonists reduced renal outcomes in people with type 2 diabetes at risk for
Abstract Hertzel C Gersteinet al
Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high glycated haemoglobin A1c (HbA1c) concentrations.
We assessed the effect of the GLP-1
Pancreatic beta cells that do not produce sufficient insulin in people with type 2 diabetes (T2D) are not permanently damaged during the early stages of the disease and can be restored to normal function through the removal of excess fat in the cells, according to a study entitled “Remission of Type
SAN FRANCISCO — As automated insulindelivery is rapidly evolving, interchangeability between insulin pumps and sensors on the various platforms is emerging as a key component to moving the field forward.
Here at the American Diabetes Association (ADA) 2019 Scientific Sessions, many attendees who
Dr. Roy Beck on CGM Accuracy and Use: “The benefit is far exceeding the burden now.”
Jaeb Center’s Dr. Roy Beck provided a very positive overview of continuous glucose monitor (CGM) options in the US, covering the four available systems: Dexcom’s G6, Abbott’s FreeStyle Libre, Medtronic’s
SAN FRANCISCO — Young people who were diagnosed with type 2 diabetes in their early teens had an "alarming" high rate of diabetes-associated complications by the time they were in their mid-20s, in new research.
Moreover, among more
The question about real-world evidence is no longer whether data collected during routine clinical processes can be useful, but rather, how can it best be used?
Mikhail Kosiborod, MD
“In recent years we have several examples of large, international comparative effectiveness studies showing that on a
A pair of experts addressed about how intensive therapy should be to lower low-density lipoprotein (LDL) cholesterol during Friday’s session Is Very Aggressive Lowering of LDL Cholesterol Worthwhile?
Steven E. Nissen, MD, MACC
Arguing in favor of aggressive therapy, Steven E. Nissen, MD, MACC,
Recent clinical trials studying the safety and efficacy of sodium-glucose co-transporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists in patients with diabetes have created opportunities for collaboration between cardiologists, diabetologists, primary health and
SAN FRANCISCO — Vitamin D3 supplementation in people at high risk of developing diabetes but who did not have vitamin Dinsufficiency does not reduce the chances of developing the disease compared with placebo, the new results of a randomized, placebo-controlled trial show.
The findings from the
Intensive insulin management is currently the only option for effective treatment of type 1 diabetes. Recent data from the T1D Exchange (T1DX) registry (1), which comprises leading U.S.
Läkemedelsutredningen lever inte upp till förväntningarna. Ett redan komplext system föreslås bli ännu mer svåröverskådligt. Det skriver företrädare för 16 patientorganisationer på SvD debatt i gårdagens tidning.Debattörerna anser att det är
The American Diabetes Association (ADA) 79th Scientific Sessions is right around the corner!
The biggest scientific diabetes conference of the year will take place in San Francisco, California from June 7-11!
Below is a preview of what we’re
Sida 3 av 11